Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Artículo original

Año: 2022

Ruiz-Villaverde, R; Rodriguez-Fernandez-Freire, L; Perez-Gil, A; Font-Ugalde, P; Galan-Gutierrez, M

Título: LIFE-BASEL

• Q2